Aprea’s Q3 2026 Net Loss Widens to $4.81 Million as Trial Expands
Photo: TokenPost
Aprea Therapeutics posted a third-quarter 2026 net loss of $4.81 million as spending on its APR-1051 cancer trial rose and the study expanded to nine active sites. The loss for the quarter ended Sept. 30 compared with $2.97 million in Q3 2025. Basic and diluted loss per share narrowed to $0.09 from $0.47 over the same period. Aprea’s weighted-average common shares rose to 53.68 million from 6.37 million a year earlier. The 2026 figure counted 39.8 million shares issuable through warrants exercisable for nominal consideration.
Source: TokenPost
